Protalix BioTherapeutics, Inc.
PLX
$1.98
$0.021.02%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 269.98% | -48.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 269.98% | -48.90% | |||
| Cost of Revenue | -82.44% | 182.41% | |||
| Gross Profit | 305.92% | -251.00% | |||
| SG&A Expenses | -13.47% | 20.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.53% | -12.34% | |||
| Operating Income | 553.97% | -318.58% | |||
| Income Before Tax | 542.65% | -313.31% | |||
| Income Tax Expenses | 287.91% | 727.59% | |||
| Earnings from Continuing Operations | 432.79% | -333.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 432.79% | -333.72% | |||
| EBIT | 553.97% | -318.58% | |||
| EBITDA | 604.57% | -270.64% | |||
| EPS Basic | 431.50% | -333.00% | |||
| Normalized Basic EPS | 541.33% | -311.86% | |||
| EPS Diluted | 417.92% | -333.00% | |||
| Normalized Diluted EPS | 524.27% | -316.76% | |||
| Average Basic Shares Outstanding | 0.43% | 0.29% | |||
| Average Diluted Shares Outstanding | 4.45% | -1.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||